- Estimated Market Cap of Approximately KRW 386.8 Billion Based on Reference Offering Price of USD 9.50 per Share
- Nasdaq Review Underway Following SEC Filing
- Pursuing Entry into 'Nasdaq Global Market' — an Uncommon Path for Korean Biotech Companies
- Subsidiary Listing Expected to Enhance Parent Company's Equity Value, Royalty Income, and Financial Synergies

ROKIT Healthcare (KOSDAQ: 376900), a specialist in AI-driven hyper-personalized organ regeneration platforms, announced on May 11 through an amended disclosure that its 100%-owned U.S. subsidiary, ROKIT America, has submitted a Form S-1/A registration statement amendment to the U.S. Securities and Exchange Commission (SEC) in connection with its planned Nasdaq listing, and has finalized the key terms of the offering.

According to the disclosure, ROKIT America plans to offer 2,631,579 newly issued common shares, bringing the total shares outstanding post-offering to 27,631,679. The expected offering price range under the SEC S-1/A is USD 8.50 to USD 10.50 per share, with a reference offering price of USD 9.50 — the midpoint of the range. Based on this reference price, the estimated market capitalization stands at approximately USD 262.5 million, or roughly KRW 386.8 billion.

The company described this milestone as a critical step for ROKIT America to launch full-scale commercial operations across North and South America, leveraging ROKIT Healthcare's AI organ regeneration platform technology — and to have its growth potential validated in the world's largest capital market.

Notably, ROKIT America is pursuing entry into the 'Nasdaq Global Market' — a market with stricter listing requirements and higher review standards — rather than the 'Nasdaq Capital Market' typically favored by smaller Korean biotech companies. The strategy is to strengthen credibility with institutional investors while elevating the brand's global standing.

■ Building an Integrated AI Regenerative Medicine Platform Across the Americas

ROKIT America plans to grow into a comprehensive AI regenerative medicine platform company serving North and South America. Current initiatives include: ▲ collaboration with Northwell Health, the largest healthcare system on the U.S. East Coast, on AI-driven organ regeneration platform development; ▲ an AI-based chronic kidney disease (CKD) prediction royalty business; ▲ research partnerships with Harvard Medical School-affiliated institutions on cartilage and kidney regeneration; and ▲ skin and cartilage regeneration projects in South America.

Building on these foundations, the company plans to fully operationalize a business model integrating AI organ regeneration platform clinical expansion, digital healthcare services, NMN-based longevity (reverse aging) solutions, and a South American hospital network. By simultaneously conducting direct sales, services, regulatory affairs, and licensing operations in the U.S., ROKIT America aims to drive revenue growth across the Americas.

■ Establishing a Dual Value-Creation Structure for Parent and Subsidiary Shareholders

From a financial perspective, this listing is expected to serve as a significant catalyst for ROKIT Healthcare. The company currently holds 100% of ROKIT America's shares and expects to retain approximately 90% ownership following the completion of the offering. Should ROKIT America receive a valuation from U.S. capital markets, the equity value of ROKIT Healthcare's stake is also expected to come into focus.

In addition, establishing a direct fundraising base for the local subsidiary will enable both the parent and subsidiary to focus on their respective business domains, while also accelerating the pace of expansion in the Americas. As North and South American sales revenue and royalty income ramp up, the financial and operational synergies between the two entities are expected to strengthen further.

■ Redefining the Global Standard for K-Bio AI Regenerative Medicine

ROKIT Healthcare emphasized that ROKIT America is not merely a local sales entity, but a strategic hub for advancing into the Americas market — backed by AI-based organ prediction, reverse aging and prevention capabilities, organ regeneration technology, and platform scalability. The company anticipates that the Nasdaq Global Market listing will serve as a turning point for ROKIT's technology and business scalability to receive in-depth evaluation from global capital markets.

A ROKIT Healthcare spokesperson stated, "This Nasdaq listing initiative will serve as an opportunity for South Korea's AI regenerative medicine technology to be reassessed as a global first mover," adding, "We will establish ourselves as a leader in the global AI healthcare platform, starting with the North and South American markets."

The company also noted, "The listing schedule and final offering terms are subject to SEC registration effectiveness, Nasdaq listing approval, market conditions, and discussions with the underwriter," and pledged to "communicate transparently with the market and shareholders as the relevant procedures are confirmed."